Literature DB >> 7296003

Prognostic relevance of thymidine kinase isozymes in adult non-Hodgkin's lymphoma.

P H Ellims, T Eng Gan, G Medley, M B Van Der Weyden.   

Abstract

To determine whether kinase (TK) isozyme status adds clinically useful information in adult non-Hodgkin's lymphoma (NHL), we have analyzed peripheral blood plasma and lymphocytes of 44 patients with NHL for either TK1 or TK2 isozyme activity. On the basis of isozyme status, patients could be divided into two groups that did not differ significantly with respect to known determinants for survival. The median survival of patients exhibiting peripheral blood TK1 thymidine kinase activity was 40 wk and that of individuals with TK2 activity was in excess of 200 wk. These data suggest that peripheral blood TK1 isozyme is a useful independent biochemical marker for a subgroup of NHL who respond poorly to current therapy and thus require new therapeutic approaches.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7296003

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  11 in total

Review 1.  Thymidine kinase: a tumor marker with prognostic value for non-Hodgkin's lymphoma and a broad range of potential clinical applications.

Authors:  M Hallek; L Wanders; S Strohmeyer; B Emmerich
Journal:  Ann Hematol       Date:  1992-07       Impact factor: 3.673

2.  Serum thymidine kinase in diagnosis and follow-up of the small cell carcinoma of the lung.

Authors:  V Abbasciano; L Graziano; D Arcudi; G Felisatti; A R Cavallini; M G Reali; N Calia; S Campi; C Guglielmini
Journal:  Med Oncol Tumor Pharmacother       Date:  1991

3.  Human thymidine kinase: purification and some properties of the TK1 isoenzyme from placenta.

Authors:  P H Ellims; T E Gan; L Cosgrove
Journal:  Mol Cell Biochem       Date:  1982-06-11       Impact factor: 3.396

4.  3'-deoxy-3'-[18F]fluorothymidine positron emission tomography for response assessment in soft tissue sarcoma: a pilot study to correlate imaging findings with tissue thymidine kinase 1 and Ki-67 activity and histopathologic response.

Authors:  Matthias R Benz; Johannes Czernin; Martin S Allen-Auerbach; Sarah M Dry; Piriya Sutthiruangwong; Claudio Spick; Caius Radu; Wolfgang A Weber; William D Tap; Fritz C Eilber
Journal:  Cancer       Date:  2011-10-21       Impact factor: 6.860

5.  Thymidine kinase isoenzymes in human acute monocytic leukemia.

Authors:  B Munch-Petersen; G Tyrsted
Journal:  Mol Cell Biochem       Date:  1985-03       Impact factor: 3.396

6.  Elevated serum thymidine kinase activity in patients with acute viral hepatitis.

Authors:  K Tanaka; T Sishido; M Morimoto; S Inoue; Y Takamura; M Masumura
Journal:  Gastroenterol Jpn       Date:  1993-02

7.  Serum thymidine kinase in acute leukaemia.

Authors:  H Hagberg; S Gronowitz; A Killander; C Källander; B Simonsson; C Sundström; G Oberg
Journal:  Br J Cancer       Date:  1984-04       Impact factor: 7.640

8.  The use of serum deoxythymidine kinase as a prognostic marker, and in the monitoring of patients with non-Hodgkin's lymphoma.

Authors:  J S Gronowitz; H Hagberg; C F Källander; B Simonsson
Journal:  Br J Cancer       Date:  1983-04       Impact factor: 7.640

9.  Additive risk survival model with microarray data.

Authors:  Shuangge Ma; Jian Huang
Journal:  BMC Bioinformatics       Date:  2007-06-08       Impact factor: 3.169

10.  Thymidine kinase activities in mononuclear leukocytes and serum from breast cancer patients.

Authors:  P G McKenna; K L O'Neill; W P Abram; B M Hannigan
Journal:  Br J Cancer       Date:  1988-06       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.